Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
In a revised medical policy, Aetna said it would continue to cover NIPT for high-risk pregnancies, but not average-risk ones.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
Natera said that the new product would further establish the company as a one-stop shop in the reproductive health market from pre-pregnancy through birth.
Natera's testing volumes increased but revenues declined due to achieving in-network status with payors and being reimbursed at a lower rate.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
The GW Index outperformed the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
Natera discussed its plans to move into the whole-genome newborn screening market and provided updates on its NIPT and oncology businesses.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.